Objective: To study the effect of Jiawei Erchentang polycystic change

endocrine and metabolism in patients with polycystic ovary syndrome (PCOS). Method: A total of 157 cases of PCOS patients treated in our hospital from March 2015 to March 2016 were selected in this study

and divided into two groups by the random number table

with 78 cases in clinical group and 79 in control group. Patients in control group were treated with cyproterone acetate tablets. In addition to the therapy of the control group

the clinical group was also given Jiawei Erchentang. Then efficacy

polycystic change

endocrine and metabolism were compared. Result: The total effective rate of control group was 81.01%

while that of clinical group was 94.87%

with a significant difference (P<0.05). Compared with before treatment

ovarian volume and ovarian follicle conditions of two groups after treatment decreased (P<0.05). Compared with control group

ovarian volume and ovarian follicle conditions of the experimental group were lower (P<0.05). Compared with before treatment

luteotropic hormone (LH)

follicle-stimulating hormone (FSH) and testosterone (T) of two groups after treatment decreased

while estradiol (E2) increased (P<0.05). Compared with control group

LH

FSH and T of the experimental group were lower after treatment

while E2 was higher (P<0.05). Compared with before treatment

glucolipid metabolism indexes

including hemoglobin Alc (HbA1c)

fasting insulin (FINS)

insulin resistance index (HOMA-IR)

total cholesterol (TC)

triglycerid (TG) of two groups after treatment decreased (P<0.05). Compared with before treatment

visfatin (VF) and leptin (LEP) of two groups after treatment decreased

while adiponectin (APN) increased (P<0.05). Compared with control group

VF and LEP of the experimental group were lower after treatment

while APN was higher (P<0.05). Conclusion: Jiawei Erchentang has a better effect on PCOS

and can significantly improve polycystic change

endocrine and metabolism

thus is worth clinical promotion.